Protalix BioTherapeutics Inc
WKN: A2PWSL / ISIN: US74365A3095Protalix!
| eröffnet am: | 16.11.15 13:21 von: | iwanooze |
| neuester Beitrag: | 24.04.21 23:13 von: | Sophiebsxna |
| Anzahl Beiträge: | 77 | |
| Leser gesamt: | 35384 | |
| davon Heute: | 5 | |
bewertet mit 3 Sternen |
||
|
Seite:
1
|
||
16.11.15 13:27
#2
iwanooze
postive phase2 news!
http://phx.corporate-ir.net/...&p=irol-newsArticle&ID=2112566
in fra
http://www.boerse-frankfurt.de/de/aktien/...utics+inc+ag+US74365A1016
0,880 : 0,910
in fra
http://www.boerse-frankfurt.de/de/aktien/...utics+inc+ag+US74365A1016
0,880 : 0,910
16.11.15 13:40
#3
tbhomy
SEC Form S-3 - Offering
Company: PROTALIX BIOTHERAPEUTICS, ... (PLX)
Form Type: S-3
Filing Date: 11/13/2015
http://www.sec.gov/edgar.shtml
"The aggregate public offering price of the securities that we may offer through this prospectus will be up to $100,000,000."
"We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, at the market offerings, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers."
Form Type: S-3
Filing Date: 11/13/2015
http://www.sec.gov/edgar.shtml
"The aggregate public offering price of the securities that we may offer through this prospectus will be up to $100,000,000."
"We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, at the market offerings, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers."
16.11.15 13:48
#4
iwanooze
strong decline in short interest!
http://money.cnn.com/news/newsfeeds/articles/...ire/11G072031-001.htm
16.11.15 16:13
#5
Chalifmann3
noch mal bitte ?
Warum sind den diese Israelischen Teile 2007 bis 50 gestiegen,war da grad der rinderwahn ausgebrochen ?
Sach nicht Ivan,du bist auf den letzten Drücker noch in Kalobios rein ??
Sach nicht Ivan,du bist auf den letzten Drücker noch in Kalobios rein ??
16.11.15 16:36
#7
Chalifmann3
?
Kann man hier auf Ariva nicht in ganzen Sätzen sprechen (aus Stochckat halt ich mich raus) ? Ich frag ja auch schon aus Mitleid garnicht mehr,ob du dich selber für einen Tradingexperten hälst,aber vielleicht kannst du mir doch weiterhelfen bei einer klitzekleinen nicht ganz unbedeutenden Frage:
Hälst du Futureworld (FWDG) für einen Scam (FRAUD),oder ist das eine "Jahrtausenchance"? Die geben sich schon jetzt als zukünftiges Powerhouse,und ich kann nicht beurteilen,ob da was dran ist ?
hm ?
Hälst du Futureworld (FWDG) für einen Scam (FRAUD),oder ist das eine "Jahrtausenchance"? Die geben sich schon jetzt als zukünftiges Powerhouse,und ich kann nicht beurteilen,ob da was dran ist ?
hm ?
27.12.16 17:16
#9
apfelrücken
schnelle Prozente möglich
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
GlobeNewswire•December 27, 2016
CARMIEL, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX) (the “Company”) announced today the confirmation of the recent letter of intent to purchase alfataliglicerase to treat Gaucher patients in Brazil by the Brazilian Ministry of Health (the “Brazilian Ministry”). The Brazilian Ministry’s order consists of a number of shipments during 2017 for a total of approximately $24.3 million. Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes. The size of the final shipment of this order represents annual revenues of approximately $42 million.
“This order for alfataliglicerase will further bolster our liquidity, and we expect it to bring us close to the breakeven point for the fourth quarter of 2017. We also anticipate having data from a number of our ongoing clinical programs during 2017,” said Mr. Moshe Manor, Protalix’s President and Chief Executive Officer. “The upcoming year will be an exciting one for our company as our narrative is changing and we now have the ability to realize significant potential clinical and commercial value-creating opportunities.”
Gaucher disease is a rare lysosomal storage disorder. Alfataliglicerase is a plant cell-expressed form of the glucocerebrosidase enzyme that was approved by the Brazilian National Health Surveillance Agency in March 2013 for the long-term treatment of adults with Type I Gaucher disease and in November 2016 for the long-term treatment of children four years of age and above with Type I Gaucher disease.
The Company owns all rights to alfataliglicerase in Brazil.
https://finance.yahoo.com/news/...s-confirmation-order-123000216.html
GlobeNewswire•December 27, 2016
CARMIEL, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX) (the “Company”) announced today the confirmation of the recent letter of intent to purchase alfataliglicerase to treat Gaucher patients in Brazil by the Brazilian Ministry of Health (the “Brazilian Ministry”). The Brazilian Ministry’s order consists of a number of shipments during 2017 for a total of approximately $24.3 million. Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes. The size of the final shipment of this order represents annual revenues of approximately $42 million.
“This order for alfataliglicerase will further bolster our liquidity, and we expect it to bring us close to the breakeven point for the fourth quarter of 2017. We also anticipate having data from a number of our ongoing clinical programs during 2017,” said Mr. Moshe Manor, Protalix’s President and Chief Executive Officer. “The upcoming year will be an exciting one for our company as our narrative is changing and we now have the ability to realize significant potential clinical and commercial value-creating opportunities.”
Gaucher disease is a rare lysosomal storage disorder. Alfataliglicerase is a plant cell-expressed form of the glucocerebrosidase enzyme that was approved by the Brazilian National Health Surveillance Agency in March 2013 for the long-term treatment of adults with Type I Gaucher disease and in November 2016 for the long-term treatment of children four years of age and above with Type I Gaucher disease.
The Company owns all rights to alfataliglicerase in Brazil.
https://finance.yahoo.com/news/...s-confirmation-order-123000216.html
28.12.16 10:17
#10
apfelrücken
sehr gute Momentaufnahme, lesen !!
http://seekingalpha.com/instablog/...sults-announced-within-two-weeks
28.12.16 11:20
#11
apfelrücken
manchmal kann Börse einfach sein...
On December 27, 2016 Protalix announced that the Brazilian Ministry of Health will purchase about $24M of the company's FDA approved alfataliglicerase to treat Gaucher patients in Brazil.
The company forecasts $42M in revenues in 2017, and nearing break-even in 4Q 2017. Company officials assert that they are well-funded through the end of 2019.
The company expects to release top line results for its ongoing AIR DNase Phase 2 clinical trials within the next two weeks per a recent press release.
The PLX share price is grossly undervalued as will be seen in this article. Analysts have a BUY rating on the stock with an average $2.4/share price target.
seekingalpha.com/instablog/...sults-announced-within-two-weeks
The company forecasts $42M in revenues in 2017, and nearing break-even in 4Q 2017. Company officials assert that they are well-funded through the end of 2019.
The company expects to release top line results for its ongoing AIR DNase Phase 2 clinical trials within the next two weeks per a recent press release.
The PLX share price is grossly undervalued as will be seen in this article. Analysts have a BUY rating on the stock with an average $2.4/share price target.
seekingalpha.com/instablog/...sults-announced-within-two-weeks
28.12.16 20:44
#12
apfelrücken
läuft, aktuell kurz vor 0,4 $
http://www.nasdaq.com/de/symbol/plx/real-time
29.12.16 20:36
#13
apfelrücken
heute wieder 20%
und Hammerumsatz
http://www.nasdaq.com/de/symbol/plx/real-time
Bis Mitte Januar sind 1$ möglich
http://www.nasdaq.com/de/symbol/plx/real-time
Bis Mitte Januar sind 1$ möglich
30.12.16 13:50
#14
4Gold
Sieht auch vom Chart her gut aus...
Bis 0,65 $ ist auf jeden Fall mindestens Potential zu steigen, bei guten Nachrishten auch bis 1 $.
Angehängte Grafik:
chart_year_protalixbiotherapeutics.png (verkleinert auf 26%)
chart_year_protalixbiotherapeutics.png (verkleinert auf 26%)
30.12.16 19:28
#15
apfelrücken
hält sich sehr gut nach dem starken Anstieg
could run up... von heute:
http://marketexclusive.com/...emktplx-run-interim-cf-data/55929/?icd1
Double digit gains across a session or two in small cap biotech aren’t all that rare. Low floats can combine with speculative volume inflow to push a company’s capitalization well into a spike, and indeed, there’s a whole bunch of traders that seek out these opportunities, and these opportunities alone. That said, more often than not, the driver behind the speculative volume inflow is valid, and it can hint at further gains near term, if the catalyst behind the driver proves positive.
Here’s one that illustrates this concept perfectly.
The company is called Protalix Biotherapeutics Inc (NYSEMKT:PLX), and it’s a small cap biotech with a development program targeting inflammatory conditions, including cystic fibrosis (CF) and Fabry. It’s also got an approved therapy called taliglucerase alfa. This one’s a Gaucher disease drug, built on its proprietary ProCellEx platform, which the FDA gave a green light to back in 2012, and which the company has since licensed globally (apart from in Brazil) to Pfizer Inc. (NYSE:PFE).
Anyway, back to the present. The company is up more than 20% on its Thursday open, on a spike in volume. There have been no real fundamental developments over the last couple of days (there was a Gaucher order announcement early week but that’s already been priced in), so why is the company running? Well, it’s currently investigating one of its lead development assets, AIR DNase (PRX-110), under investigation for the treatment of CF.
The trial has been pretty closely followed since some promising early stage data hit press, and Protalix has stated that it will put out interim data from the study during the first week of January.
If the data comes out as a primary hit, there’s plenty more upside on offer from that which we’ve already seen. If it misses, Protalix will likely give back this 20% run, and perhaps a little more, to the markets. So the question is, what are the chances of a hit? Let’s try and figure it out.
PRX-110 is a proprietary plant cell-expressed recombinant form of human deoxyribonuclease I (DNase1). The company designed it to be resistant to actin inhibition. Current CF therapy includes an SOC DNase1. It’s designed to reduce the viscosity of sputum, which is a primary issue with CF, and leads to infections and lung function compromise. Current DNasel1, however, is not resistant to actin, and actin acts to impair the impact it has on the sputum. Basically, it breaks the DNase1 down, reducing its efficacy, and necessitating higher dosing. The version that Protalix has created is resistant to this enzymatic breakdown, so theoretically, it should build on the efficacy of SOC DNase1. If it does, it could quickly eat away at the market for the commercialized version, called Pulmozyme and marketed by Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s Genentech.
That’s a $700 million annual market.
So what are the chances of approval? To date we’ve only got healthy volunteer data derived from the clinic, so while we know it’s safe, we’ve not got too much insight into clinical benefit. With that said, we’ve seen some evidence of benefit for a similar drug in Fabry, and there’s plenty of legacy data supporting the mechanism of action. The science is sound (if actin stops current SOC reaching maximum efficiency, then making the current SOC resistant to actin should make it more effective) and all it really needs to do in this trial is show equivalence. Why? Because these are patients that have already been treated with SOC, and for which the latter is not working particularly well.
Primary is safety on this one, so while that’s got to be a hit, we’re not particularly interested in it. Instead, we’re looking at two secondary measures, area under the curve and change from baseline to end of treatment in FEV1. FEV1 is an industry standard measure of CF severity, so if the company can show that a patient has an improved FEV1 after treatment with 110, then there’s some solid implied clinical benefit.
It’s interim (study completion is set for May next year) so keep that in mind, but t could really impact Protalix’s chances of getting this one through to commercialization if it comes out as indicative of efficacy.
http://marketexclusive.com/...emktplx-run-interim-cf-data/55929/?icd1
Double digit gains across a session or two in small cap biotech aren’t all that rare. Low floats can combine with speculative volume inflow to push a company’s capitalization well into a spike, and indeed, there’s a whole bunch of traders that seek out these opportunities, and these opportunities alone. That said, more often than not, the driver behind the speculative volume inflow is valid, and it can hint at further gains near term, if the catalyst behind the driver proves positive.
Here’s one that illustrates this concept perfectly.
The company is called Protalix Biotherapeutics Inc (NYSEMKT:PLX), and it’s a small cap biotech with a development program targeting inflammatory conditions, including cystic fibrosis (CF) and Fabry. It’s also got an approved therapy called taliglucerase alfa. This one’s a Gaucher disease drug, built on its proprietary ProCellEx platform, which the FDA gave a green light to back in 2012, and which the company has since licensed globally (apart from in Brazil) to Pfizer Inc. (NYSE:PFE).
Anyway, back to the present. The company is up more than 20% on its Thursday open, on a spike in volume. There have been no real fundamental developments over the last couple of days (there was a Gaucher order announcement early week but that’s already been priced in), so why is the company running? Well, it’s currently investigating one of its lead development assets, AIR DNase (PRX-110), under investigation for the treatment of CF.
The trial has been pretty closely followed since some promising early stage data hit press, and Protalix has stated that it will put out interim data from the study during the first week of January.
If the data comes out as a primary hit, there’s plenty more upside on offer from that which we’ve already seen. If it misses, Protalix will likely give back this 20% run, and perhaps a little more, to the markets. So the question is, what are the chances of a hit? Let’s try and figure it out.
PRX-110 is a proprietary plant cell-expressed recombinant form of human deoxyribonuclease I (DNase1). The company designed it to be resistant to actin inhibition. Current CF therapy includes an SOC DNase1. It’s designed to reduce the viscosity of sputum, which is a primary issue with CF, and leads to infections and lung function compromise. Current DNasel1, however, is not resistant to actin, and actin acts to impair the impact it has on the sputum. Basically, it breaks the DNase1 down, reducing its efficacy, and necessitating higher dosing. The version that Protalix has created is resistant to this enzymatic breakdown, so theoretically, it should build on the efficacy of SOC DNase1. If it does, it could quickly eat away at the market for the commercialized version, called Pulmozyme and marketed by Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s Genentech.
That’s a $700 million annual market.
So what are the chances of approval? To date we’ve only got healthy volunteer data derived from the clinic, so while we know it’s safe, we’ve not got too much insight into clinical benefit. With that said, we’ve seen some evidence of benefit for a similar drug in Fabry, and there’s plenty of legacy data supporting the mechanism of action. The science is sound (if actin stops current SOC reaching maximum efficiency, then making the current SOC resistant to actin should make it more effective) and all it really needs to do in this trial is show equivalence. Why? Because these are patients that have already been treated with SOC, and for which the latter is not working particularly well.
Primary is safety on this one, so while that’s got to be a hit, we’re not particularly interested in it. Instead, we’re looking at two secondary measures, area under the curve and change from baseline to end of treatment in FEV1. FEV1 is an industry standard measure of CF severity, so if the company can show that a patient has an improved FEV1 after treatment with 110, then there’s some solid implied clinical benefit.
It’s interim (study completion is set for May next year) so keep that in mind, but t could really impact Protalix’s chances of getting this one through to commercialization if it comes out as indicative of efficacy.
30.12.16 23:02
#16
4Gold
@ apfelrücken - Wenn es wirklich so kommt
sehen wir hier noch ganz andere Kurse ;-)) Ich bin dabei.
30.12.16 23:39
#17
apfelrücken
ja, 4Gold, innerhalb der nächsten zwei Wochen
kommen Ergebnisse aus Phase II. Der Januar beginnt also mit Spannung.
http://seekingalpha.com/article/...&commenter=1&comments=show
The company expects to release top line results for its ongoing AIR DNase Phase 2 clinical trials within the next two weeks per a recent press release.
Bis dahin tippe ich auf stetiges - zumindest leichtes - Ansteigen. Bei - wie von mir erwartet -
positiven Aussagen und Aussichten im Januar gehts schneller weiter im Kurs.
Ich steh voll hinter "The PLX share price is grossly undervalued as will be seen in this article. Analysts have a BUY rating on the stock with an average $2.4/share price target."
Guten Rutsch in das für Dich hoffentlich erfolgreiche Jahr 2017. Bis dahin...
http://seekingalpha.com/article/...&commenter=1&comments=show
The company expects to release top line results for its ongoing AIR DNase Phase 2 clinical trials within the next two weeks per a recent press release.
Bis dahin tippe ich auf stetiges - zumindest leichtes - Ansteigen. Bei - wie von mir erwartet -
positiven Aussagen und Aussichten im Januar gehts schneller weiter im Kurs.
Ich steh voll hinter "The PLX share price is grossly undervalued as will be seen in this article. Analysts have a BUY rating on the stock with an average $2.4/share price target."
Guten Rutsch in das für Dich hoffentlich erfolgreiche Jahr 2017. Bis dahin...
31.12.16 10:26
#18
apfelrücken
der Fond weiß schon, warum er
zugeschlagen hat...
filling vom 23.12.2016
may be deemed to be the beneficial owner of 6,523,399 shares of Common Stock held by the Highbridge Funds.
http://secfilings.nasdaq.com/....&FormType=SC%2013G&View=html
filling vom 23.12.2016
may be deemed to be the beneficial owner of 6,523,399 shares of Common Stock held by the Highbridge Funds.
http://secfilings.nasdaq.com/....&FormType=SC%2013G&View=html
31.12.16 16:28
#19
4Gold
apfelrücken, auch Dir einen guten Rutsch
in das neue Jahr. Und wenn schon ein Fond drauf aufmerksam geworden ist, sind die großen Investoren nicht weit entfernt......... Gute Investition für 2017.
03.01.17 14:37
#20
Gropius
Bitte !
http://ih.advfn.com/p.php?pid=nmona&article=73526095
Phase 2 positiv
Phase 2 positiv
03.01.17 15:18
#21
apfelrücken
@Gropius: hast Du was anderes erwartet
nach dem newsfloat die letzten Wochen ?
Premarket 1 Mio Stücke gehandelt, auf 80 Cent Ende der Woche.
So kann das Jahr starten. Hätte bloß nicht heute mit der Veröffentlichung gerechnet.
http://finance.yahoo.com/news/...nces-positive-interim-123000436.html
Premarket 1 Mio Stücke gehandelt, auf 80 Cent Ende der Woche.
So kann das Jahr starten. Hätte bloß nicht heute mit der Veröffentlichung gerechnet.
http://finance.yahoo.com/news/...nces-positive-interim-123000436.html
03.01.17 15:20
#22
apfelrücken
hier das filling dazu
http://stocknewsflow.com/...0114420417000033_0001144204-17-000033ppp2
05.01.17 22:54
#24
4Gold
Der "Markt" muss nun erst
einmal den Anstieg verarbeiten und Kraft sammeln um das noch offene Gap zu schließen. Kann ganz schnell gehen....
Angehängte Grafik:
chart_quarter_protalixbiotherapeutics.png (verkleinert auf 26%)
chart_quarter_protalixbiotherapeutics.png (verkleinert auf 26%)
13.01.17 19:58
#25
4Gold
Der Chart macht sich zur
Schließung des Gap bereit. An der Amex wird wohl der Wert gerade erkannt ;-))............
Seite:
1